CTMX: Lead ADC shows promising efficacy and safety in late-line CRC, with broad expansion plans
Masked biologics technology enables targeting of challenging cancer antigens, with lead ADC showing strong efficacy and manageable GI toxicity in late-line CRC. Dose optimization and registrational plans are underway, with expansion into other GI cancers and a masked cytokine program in melanoma.Ba…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.